Efficacy and safety of GS1-144, a novel neurokinin 3 receptor antagonist, for moderate-to-severe vasomotor symptoms associated with menopause in Chinese women: a randomized, double-blind, placebo-controlled phase 2 trial.
- DOI
- 10.1097/gme.0000000000002748
- Published
- 2026 Aug 1
- Container
- Menopause (New York, N.Y.)
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1097/gme.0000000000002748,
title = {Efficacy and safety of GS1-144, a novel neurokinin 3 receptor antagonist, for moderate-to-severe vasomotor symptoms associated with menopause in Chinese women: a randomized, double-blind, placebo-controlled phase 2 trial.},
author = {Wang Y and Wang X and Wang W and Lin J and He Y and Chen H and Shou H and Ai X and Zhang Q and Cai Y and Wu Y and Guo R and Hu L and Chen H and Xiang W and Pan C and Yu Q},
year = {2026},
journal = {Menopause (New York, N.Y.)},
doi = {10.1097/gme.0000000000002748},
url = {https://doi.org/10.1097/gme.0000000000002748}
}RIS
TY - JOUR TI - Efficacy and safety of GS1-144, a novel neurokinin 3 receptor antagonist, for moderate-to-severe vasomotor symptoms associated with menopause in Chinese women: a randomized, double-blind, placebo-controlled phase 2 trial. AU - Wang Y AU - Wang X AU - Wang W AU - Lin J AU - He Y AU - Chen H AU - Shou H AU - Ai X AU - Zhang Q AU - Cai Y AU - Wu Y AU - Guo R AU - Hu L AU - Chen H AU - Xiang W AU - Pan C AU - Yu Q PY - 2026 JO - Menopause (New York, N.Y.) DO - 10.1097/gme.0000000000002748 UR - https://doi.org/10.1097/gme.0000000000002748 ER -
APA
Y, W., X, W., W, W., J, L., Y, H., H, C., H, S., X, A., Q, Z., Y, C., Y, W., R, G., L, H., H, C., W, X., C, P., & Q, Y. (2026). Efficacy and safety of GS1-144, a novel neurokinin 3 receptor antagonist, for moderate-to-severe vasomotor symptoms associated with menopause in Chinese women: a randomized, double-blind, placebo-controlled phase 2 trial.. Menopause (New York, N.Y.). https://doi.org/10.1097/gme.0000000000002748
Source records
- pubmed · retrieved 2026-09-27T11:06:31.463Z